BMS-986408 / BMS - LARVOL DELTA

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=101 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | N=402 ➔ 101 | Trial primary completion date: Oct 2025 ➔ Aug 2024

Combination therapy • Enrollment change • Metastases • Trial primary completion date • Melanoma • Oncology • Solid Tumor • BRAF • NRAS

First disclosure of BMS-986408: A dual inhibitor of Diacylglycerol kinases alpha and zeta for cancer therapy (ACS-Fall 2024) - "Our preclinical efforts culminated in the discovery of BMS-986408, an orally bioavailable, potent dual inhibitor of DGKs α and ζ (IC50s < 20 nM). The favorable PK profile across species was predictive of once daily dosing in human, and BMS-986408 is currently in Phase 1/2 clinical trials in patients with solid tumors."

Oncology • Solid Tumor

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=402 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Active, not recruiting | N=113 ➔ 402 | Trial completion date: Mar 2027 ➔ Oct 2025 | Trial primary completion date: Mar 2027 ➔ Oct 2025

Combination therapy • Enrollment change • Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor • BRAF • NRAS

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=113 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Melanoma • Oncology • Solid Tumor • BRAF • NRAS

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=122 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

Combination therapy • New P1/2 trial • Melanoma • Oncology • Solid Tumor • BRAF • NRAS